Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: A review

Journal of Clinical Psychopharmacology

Volumn 18, Issue 6, 1998, Pages 447-454

  Bonhomme, Norbert ^a   Esposito, Ennio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUOXETINE; FLUVOXAMINE; GEPIRONE; IPSAPIRONE; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; SEROTONIN; SEROTONIN 2 ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULPIRIDE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

DEPRESSION; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; SEROTONINERGIC SYSTEM;

ANTIDEPRESSIVE AGENTS; DOPAMINE; HUMANS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN;

EID: 0031762413     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199812000-00005     Document Type: Review

References (103)

1. Van Praag HM, Korf J. A pilot study of some kinetic aspects of the metabolism of 5-hydroxytryptamine in depressive patients. Biol Psychiatry 1971;3:105-12.
2. Åsberg M, Thorén P, Träskman L, Bertilsson L, Ringberger V. "Serotonin depression" - a biochemical subgroup within the affective disorder? Science 1976;191:478-80.
3. Mann JJ, Malone KM, Diehl DJ, Perel J, Cooper TB, Mintun MA. Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am J Psychiatry 1996;153: 174-82.
4. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 47:411-8.
5. de Montigny C, Aghajanian GK. Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain to serotonin. Science 1978;202:1303-6.
6. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987;7[suppl 6]:24S-35S.
7. Chaput Y, de Montigny C, Blier P. Effects of a selective 5-HT re-uptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1986;333:342-8.
8. Chaput Y, de Montigny C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 1991;5:219-29.
9. Artigas F. 5-HT and antidepressants: new views from microdialysis studies [letter]. Trends Pharmacol Sci 1993;14:262.
10. Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993;15:243-5.
11. 1A receptors. Eur J Pharmacol 1994;260:243-6.
12. Amt J, Overo KF, Hyttel J, Olsen R. Changes in rat dopamine- and serotonin function in vivo after prolonged administration of the specific 5-HT uptake inhibitor, citalopram. Psychopharmacology (Berl) 1984;84:457-65.
13. Lucid I, Frazer A. Changes in behavior associated with serotonin receptors following repeated treatment with antidepressant drugs. In: Seiden LS, Balster RL, eds. Behavioral pharmacology: the current status. New York: Alan R. Liss Inc., 1985:339-57.
14. Maj J, Moryl E. Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J Neural Transm Gen Sect 1992;88:143-56.
15. 2C/2B receptor function. Neuropharmacology 1994;33:1581-8.
16. Wang RY, Aghajanian GK. Enhanced sensitivity of amygdaloid neurons to serotonin and norepinephrine antidepressant treatment. Commun Psychopharmacol 1980;4:83-90.
17. Jones RSG. Long-term administration of atropine, imipramine and viloxazine alters responsiveness of rat cortical neurons to acetylcholine. Can J Physiol Pharmacol 1980;58:531-5.
18. de Montigny C, Blier P, Chaput Y. Electrophysiologically-identified serotonin receptors in the rat CNS. Effect of antidepressant treatment. Neuropharmacology 1984;23:1511-23.
19. Menkes DB, Aghajanian GK. α1-Adrenoceptor-mediated responses in the lateral geniculate nucleus are enhanced by chronic antidepressant treatment. Eur J Pharmacol 1981;74:27-35.
20. 1A-receptors, as measured by behavioural tests and receptor binding in rats. Neuropharmacology 1992;31:25-32.
21. 1A auto receptors in rats treated with fluoxetine or paroxetine. Naunyn Schmiedebergs Arch Pharmacol 1995;352:141-8.
22. 1A antagonists. Trends Neurosci 1996;19:378-83.
23. Aghajanian GK. Feedback regulation of central monoaminergic neurons: evidence for single cell recording studies. In: Youdin MBH, Lovenberg W, Sharman DF, Lagnado JR, eds. Essays in neurochemistry and neuropharmacology. Vol. 3. New York: John Wiley & Sons, 1978:1-33.
24. Moret C, Briley M. Serotonin autoreceptor subsensitivity and antidepressant activity. Eur J Pharmacol 1990;180:351-6.
25. Adell A, Artigas F. Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 1991;343:237-44.
26. Invernizzi R, Belli S, Samanin R. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 1992; 584:322-4.
27. Bel N, Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 1992;229:101-3.
28. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J Neurochem 1993;60:776-9.
29. Artigas F, Peréz V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-51.
30. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995;15:217-22.
31. Pérez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349: 1594-7.
32. Tome MB, Isaac MT, Harte R, Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997;12:81-9.
33. Jenkins SW, Robinson DS, Fabre LF Jr, Andary JJ, Messina ME, Reich LA. Gepirone in the treatment of major depression. J Clin Psychopharmacol 1990;10[suppl 3]:77S-85S.
34. 1A-receptor ligand with anxiolytic and antidepressant properties. Drugs Future 1988;13:429-39.
35. 1A partial agonists. What is their future? Drugs 1991;41:11-8.
36. Fibiger HC. Neurobiology of depression: focus on dopamine. In: Gessa G, Fratta W, Pani L, Serra G, eds. Depression and mania: from neurobiology to treatment. New York: Raven Press, 1995:1-17.
37. Willner P. Animal models of depression: validity and applications. In: Gessa G, Fratta W, Pani L, Serra G, eds. Depression and mania: from neurobiology to treatment. New York: Raven Press, 1995:19-41.
38. Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol Psychiatry 1992;32:1-17.
39. Åsberg M, Bertilsson L, Mårtensson, Scalia-Tomba G-P, Thorén P, Träskman-Bendz L. CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 1984;69:201-19.
40. Van Praag HM, Korf J. Retarded depression and the dopamine metabolism. Psychopharmacologia 1971;19:199-203.
41. Papeschi R, McClure DJ. Homovanillic and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of depressed patients. Arch Gen Psychiatry 1971;25:354-8.
42. Mayeux R. Depression in the patient with Parkinson's disease. J Clin Psychiatry 1990;51[suppl 7]:20-3.
43. Belmaker RH, Wald D. Haloperidol in normals. Br J Psychiatry 1977;131:222-3.
44. Fibiger HC, Phillips AG. Increased intracranial self-stimulation in rats after long-term administration of desipramine. Science 1981; 214:683-5.
45. Spyraki C, Fibiger HC. Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol 1981; 74:195-206.
46. Arnt J, Hyttel J, Overo KF. Prolonged treatment with the specific 5-HT-uptake inhibitor citalopram: effect on dopaminergic and serotonergic functions. Pol J Pharmacol Pharm 1984;36:221-30.
47. Maj J, Wedzony K, Klimek V. Desipramine given repeatedly enhances behavioural effects of dopamine and d-amphetamine injected into the nucleus accumbens. Eur J Pharmacol 1987;140: 179-85.
48. Klimek V, Maj J. Repeated administration of antidepressants enhances agonists affinity for mesolimbic D2-receptors. J Pharm Pharmacol 1989;41:555-8.
49. Hammer RP, Margulies JE, Lynn AB, Brady LS. Chronic fluoxetine treatment up-regulates dopamine receptors in the mesolimbic forebrain of the rat. Depression 1993;1:82-7.
50. Martin-Iverson MT, Leclere J-F, Fibiger HC. Cholinergic-dopaminergic interactions and the mechanism of action of antidepressants. Eur J Pharmacol 1983;94:193-201.
51. Serra G, Argiolas A, Klimek V, Fadda F, Gessa GL. Chronic treatment with antidepressants prevents the inhibitory effect of small doses of apomorphine on dopamine synthesis and motor activity. Life Sci 1979;25:415-24.
52. Chiodo LA, Antelman SM. Repeated tricyclic induce a progressive dopamine autoreceptor subsensitivity independent of daily drug treatment. Nature 1980;287:451-4.
53. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. Chronic desipramine enhances amphetamine-induced increases in interstitial concentrations of dopamine in the nucleus accumbens. Eur J Pharmacol 1991;195:63-73.
54. Papp M, Klimek V, Willner P. Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology (Berl) 1994;115:441-6.
55. Papp M, Muscat R, Willner P. Subsensitivity to rewarding and locomotor stimulant effects of a dopamine agonist following chronic mild stress. Psychopharmacology (Berl) 1993;110:152-8.
56. Muscat R, Papp M, Willner P. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology (Berl) 1992;109:433-8.
57. Moreau J-L, Jenck F, Martin JR, Mortas P, Haefely W. Effects of moclobemide, a new generation reversible MAO-A inhibitor, in a novel animal model of depression. Pharmacopsychiatry 1993; 26:30-3.
58. Moreau J-L, Jenck F, Martin JR, Scherschlicht R. The chronic mild stress-induced anhedonia model of depression: REM sleep abnormalities and curative effects of electroshock treatment [abstract]. Behav Pharmacol 1994;5[suppl 1]:32.
59. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 1987;93:358-64.
60. Theohar C, Fisher-Cornelssen K, Akesson HO, Ansari J, Gerlach G, Ohman R, Ose E, Stegnik AJ. Bromocriptine as antidepressant: double-blind comparative study with imipramine in psychogenic and endogenous depression. Curr Ther Res 1981;30:830-41.
61. Post RM, Gerner RH, Carman JS, Gillin JC, Jimerson DC, Goodwin FK, Bunney WE Jr. Effects of dopamine agonist piribedil in depressed patients. Arch Gen Psychiatry 1978;35:609-15.
62. Randrup A, Braestrup C. Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology (Berl) 1977;53:309-14.
63. Forrest A, Hewett A, Nicholson P. Controlled randomized group comparison of nomifensine and imipramine in depressive illness. Br J Clin Pharmacol 1977;4[suppl 2]:215S-220S.
64. Grof P, Saxena B, Daigle L, Mahutte G. Dopaminergic agonist nomifensine compared with amitriptyline: a double-blind clinical trial in acute primary depressions. Br J Clin Pharmacol 1977; 4[suppl 2]:221S-225S.
65. McClelland HA, Kerr TA, Little JC. A clinical comparison of nomifensine and amitryptyline. Br J Clin Pharmacol 1977;4[suppl 2]:233S-236S.
66. Kinney JL. Nomifensine maleate: a new second-generation antidepressant. Clin Pharmacol 1985;4:625-36.
67. Golden RN, Rudorfer MV, Sherer MA, Linnoila M, Potter WZ. Bupropion in depression. I. Biochemical effects and clinical response. Arch Gen Psychiatry 1988;45:139-43.
68. Mendis N, Hanwella DR, Weerasinghe C, Illesinghe DS, De Silva D. A double-blind comparative study: amineptine (Survector 100) versus imipramine. Clin Neuropharmacol 1989;12[suppl 2]: S58-S65.
69. Willner P. Dopaminergic mechanisms in depression and mania. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:921-31.
70. Serra G, Forgione A, D'Aquila PS, Collu M, Fratta W, Gessa GL. Possible mechanism of antidepressant effect of L-sulpiride. Clin Neuropharmacol 1990;13[suppl 1]:76-83.
71. 3) as a target for neuroleptics. Nature 1990;347:146-51.
72. 3 receptors. Neuropsychopharmacology 1994;10:242S.
73. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997;280:83-97.
74. Boyer P, Lecrubier Y. Atypical antipsychotic drugs in dysthymia: placebo controlled studies of amisulpride versus imipramine, versus amineptine. Eur Psychiatry 1996;11[suppl 3]:135S-140S.
75. de Sousa MP. Amisulpride in dysthymia: results of a naturalistic study in general practice. Eur Psychiatry 1996;11[suppl 3]: 145S-147S.
76. Smeraldi E, Haefele E, Crespi G, Casadei GL, Biondi F, Vigorelli E. Amisulpride versus fluoxetine in dysthymia: preliminary results of a double-blind comparative study. Eur Psychiatry 1996; 11[suppl 3]:141S-143S.
77. Puech AJ, Rioux P, Poncelet M, Brochet D, Chermat R, Simon P. Pharmacological properties of new antipsychotic agents: use of animal models. Neuropharmacology 1981;20:1279-84.
78. Vasse M, Protais P, Costentin J, Schwartz JC. Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice. Naunyn Schmiedebergs Arch Pharmacol 1985;329:108-16.
79. Guyon A, Assouly-Besse F, Biala G, Puech AJ, Thiebot MH. Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats. Psychopharmacology (Berl) 1993;110:460-6.
80. 3 dopamine receptor antagonistic activity and limbic selectivity. J Pharmacol Exp Ther 1997;280:73-82.
81. Boyer P, Puech A. Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools. Psychiatry Psychobiol 1987;2:296-305.
82. Azmitia EC, Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 1978;179:641-68.
83. Phillipson OT. Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: a horseradish peroxidase study in the rat. J Comp Neurol 1979;187:117-44.
84. Steinbush HWM. Serotonin-immunoreactive neurons and their projections in the CNS. Classical transmitters and transmitter receptors in the CNS. Part II. In: Björklun A, Hökfelt T, Kuhar MJ, eds. Handbook of Chemical Neuroanatomy. Vol. 3. Amsterdam: Elsevier, 1984:68-125.
85. Mori S, Matsuura T, Takino T, Sano Y. Light and electron microscopic immunohistochemical studies of serotonin nerve fibers in the substantia nigra of the rat, cat and monkey. Anat Embryol (Berl) 1987;176:13-8.
86. Hervé D, Pickel VM, Joh TH, Beaudet A. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res 1987;435:71-83.
87. Spoont MR. Modulatory role of serotonin in neural information processing: implications for human psychopathology. Psychol Bull 1992;112:330-50.
88. Gerson SC, Baldessarini R. Motor effects of serotonin in the central nervous system. Life Sci 1980;27:1435-51.
89. Prisco S, Pagannone S, Esposito E. Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo. J Pharmacol Exp Ther 1994;271:83-90.
90. 1A receptor selective ligands, (R)-S-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol 1993;347:353-62.
91. Prisco S, Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br J Pharmacol 1995;116:1923-31.
92. Esposito E. An indirect action for fluoxetine on the dopamine neurotransmitter system. Trends Pharmacol Sci 1996;17:400-1.
93. Kennedy AJ, Gibson EL, O'Connell MT, Curzon G. Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioural responses to mCPP. Psychopharmacology (Berl) 1993;113:262-8.
94. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985;46:53-8.
95. Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry 1985;46:32-7.
96. 3H]-spiperone binding in rat frontal cortex and serotonin receptor mediated behaviour. Psychopharmacology (Berl) 1983;80:150-5.
97. Nelson DR, Thomas DR, Johnson AM. Pharmacological effects of paroxetine after repeated administration to animals. Acta Psychiatr Scand Suppl 1989;350:21-3.
98. Maes M, Meltzer HY. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 933-44.
99. 2 receptor changes in major depression. Biol Psychiatry 1990;27:489-96.
100. Rickels K, Schweizer E, Clary C, Fox I, Weise C. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 1994;164:802-5.
101. Fontaine R, Oontiveros A, Elie R, Kensler TT, Roberts DL, Kaplita S, Ecker JA, Faludi G. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234-41.
102. Humphrey PPA, Hartig P, Hoyer D. A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 1993;14:233-6.
103. 2 receptor subtypes: a family re-united? Trends Pharmacol Sci 1995;16:105-10.